StreetInsider.com News Articles

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026
Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027
BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.

“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

Thu, 23 Jul 2026 12:00:00 -0400

Cash position of €9.7 million as of June 30, 2026

Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027

BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update.
“During the quarter, we

ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets

Fri, 17 Jul 2026 12:00:00 -0400

LYON, France--(BUSINESS WIRE)-- Regulatory News:
Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 – ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30, 2026 :

Number of shares: 45,699

Cash balance of the liquidity account: € 126,636.84

During the 1st half of 2026, a total of:

Buy-side

298,013 shares

€ 1,619,929.17

Number of shares: 45,699

Cash balance of the liquidity account: € 126,636.84

During the 1st half of 2026, a total of:

Buy-side

298,013 shares

€ 1,619,929.17

Number of shares: 45,699

Cash balance of the liquidity account: € 126,636.84

During the 1st half of 2026, a total of:

Buy-side

298,013 shares

€ 1,619,929.17

Number of shares: 45,699

Cash balance of the liquidity account: € 126,636.84

During the 1st half of 2026, a total of:

Buy-side

298,013 shares

€ 1,619,929.17

Number of shares: 45,699

Cash balance of the liquidity account: € 126,636.84

During the 1st half of 2026, a total of:

Buy-side

298,013 shares

€ 1,619,929.17

Number of shares: 45,699

Cash balance of the liquidity account: € 126,636.84

During the 1st half of 2026, a total of:

Buy-side

298,013 shares

€ 1,619,929.17

Number of shares: 45,699

Cash balance of the liquidity account: € 126,636.84

During the 1st half of 2026, a total of:

Buy-side

298,013 shares

€ 1,619,929.17